Form 4: Journey Medical Director Lindsay Rosenwald Reports Grant of Restricted Stock Units

Journey Medical Corp Director and 10% owner, Lindsay A. Rosenwald MD, reported the acquisition of 7,173 restricted stock units, which will vest in full on June 25, 2026.

Summary

• Lindsay A. Rosenwald MD, a Director and 10% owner of Journey Medical Corp (DERM), was granted 7,173 restricted stock units (RSUs) on June 25, 2025.
• The grant was made pursuant to the Issuer's 2015 Stock Plan, as amended.
• These 7,173 restricted stock units are scheduled to vest in full on June 25, 2026.
• Following this transaction, Dr. Rosenwald directly holds 161,146 shares, which includes other restricted stock units vesting over various time periods.
• Dr. Rosenwald indirectly holds 176,470 shares through a limited liability company where he serves as the managing member, and is deemed to have voting and investment power over these shares.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director and 10% owner is generally a positive signal, indicating continued alignment of interests and commitment to the company's future performance. It's a routine compensation event rather than a major strategic announcement.

Positives

• The grant of restricted stock units to a director and 10% owner aligns management incentives with shareholder interests, promoting long-term commitment.
• This equity compensation indicates continued engagement and confidence from a significant insider in the company's future performance.

Risks

• The value of the restricted stock units is directly tied to the future performance of Journey Medical Corp's stock price, exposing the recipient to market fluctuations.
• Future dilution from the vesting of these and other restricted stock units could occur, although the impact from this specific grant of 7,173 units is minimal.

Future Outlook

The grant of restricted stock units with a future vesting date indicates an expectation of continued service from the director and aligns their long-term interests with the company's performance and shareholder value creation.

Industry Context

Insider transactions, particularly grants of equity compensation to directors and significant shareholders, are common practices across industries to align the interests of key personnel with long-term shareholder value creation. This specific filing reflects a standard compensation mechanism within the pharmaceutical or medical device sector, where Journey Medical Corp operates.

Comparison to Industry Standards

• Equity grants to directors are a standard component of compensation packages across publicly traded companies, aligning their incentives with long-term shareholder value.
• The use of restricted stock units (RSUs) is a common practice, often preferred over stock options due to their inherent value upon vesting, which can reduce the need for immediate stock price appreciation.
• The vesting schedule, a full vest after one year, is a common short-to-medium term incentive structure for director grants, though multi-year vesting is also prevalent depending on company policy and role.

Stakeholder Impact

• Shareholders: The grant aligns the interests of a significant insider with long-term shareholder value, potentially leading to more focused decision-making. There is a minor potential for dilution upon the vesting of these units.
• Management/Employees: This transaction reflects standard compensation practices for key personnel, which can contribute to retention and motivation within the company.

Next Steps

• The 7,173 restricted stock units granted to Lindsay A. Rosenwald MD are expected to vest in full on June 25, 2026.

Key Dates

Keywords

Journey Medical Corp, DERM, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Grant, Director Compensation, Lindsay A. Rosenwald, Beneficial Ownership